Outlook Therapeutics, Inc. (OTLK): Gross Profit

Annual figures by period end, from SEC filings.

$57.2K

Year ended 2025-09-30

-$2.28M

Trailing 12 months to 2026-06-30

Period ended	Gross Profit	Change YoY	Source filing
2025-09-30	$57.2K	n/a	2025-12-19, From 2024-10-01

Gross Profit at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Gross Profit	Change YoY
Outlook Therapeutics, Inc. (OTLK)	2025-09-30	$57.2K	n/a
Scinai Immunotherapeutics Ltd. (SCNI)	2025-12-31	-$2.65M	n/m
Pluri Inc. (PLUR)	2026-06-30	$453.0K	-30.7%
Humacyte, Inc. (HUMA)	2025-12-31	-$7.66M	n/a
Dyadic International Inc (DYAI)	2025-12-31	$770.5K	-66.5%
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	$4.27M	+13.0%
Alpha Cognition Inc. (ACOG)	2025-12-31	$9.62M	n/a
Zivo Bioscience, Inc. (ZIVO)	2024-12-31	$49.0K	+321.6%
Pelthos Therapeutics Inc. (PTHS)	2025-12-31	$12.81M	n/a

Compare OTLK, SCNI, PLUR, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗